Parathyroid hormone: Evolving therapeutic concepts

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose of review: Osteoporosis results from a loss of bone mass and structure such that bones break with very little trauma. To reduce bone loss and improve strength, antiresorptive agents have been instituted. Just more than a year ago, a 34-amino acid fragment of parathyroid hormone (recombinant human parathyroid hormone 1-34) was approved for the treatment of osteoporosis. The parathyroid hormone treatment works by stimulating bone formation on all bone surfaces and is referred to as an osteoanabolic agent. The purpose of this article is to review initial phase 2 and phase 3 studies that establish the effectiveness of this agent to treat osteoporosis. Recent findings: In addition, studies that use parathyroid hormone in combination with antiresorptive agents and sequentially are reviewed. Last, unresolved issues related to the duration of use of parathyroid hormone are discussed. Summary: In summary, parathyroid hormone compounds are a major advance in the treatment of osteoporosis. Additional research will enlighten clinicians on the most efficacious way to use them.

Original languageEnglish (US)
Pages (from-to)457-463
Number of pages7
JournalCurrent Opinion in Rheumatology
Volume16
Issue number4
DOIs
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Parathyroid Hormone
Osteoporosis
Bone Density Conservation Agents
Bone and Bones
Teriparatide
Therapeutics
Osteogenesis
Amino Acids
Wounds and Injuries
Research

Keywords

  • Osteoanabolic agent
  • Osteoporosis
  • Parathyroid hormone

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Parathyroid hormone : Evolving therapeutic concepts. / Lane, Nancy E.

In: Current Opinion in Rheumatology, Vol. 16, No. 4, 07.2004, p. 457-463.

Research output: Contribution to journalArticle

@article{10d8ad7fd8364092b1d257dab6ca66ac,
title = "Parathyroid hormone: Evolving therapeutic concepts",
abstract = "Purpose of review: Osteoporosis results from a loss of bone mass and structure such that bones break with very little trauma. To reduce bone loss and improve strength, antiresorptive agents have been instituted. Just more than a year ago, a 34-amino acid fragment of parathyroid hormone (recombinant human parathyroid hormone 1-34) was approved for the treatment of osteoporosis. The parathyroid hormone treatment works by stimulating bone formation on all bone surfaces and is referred to as an osteoanabolic agent. The purpose of this article is to review initial phase 2 and phase 3 studies that establish the effectiveness of this agent to treat osteoporosis. Recent findings: In addition, studies that use parathyroid hormone in combination with antiresorptive agents and sequentially are reviewed. Last, unresolved issues related to the duration of use of parathyroid hormone are discussed. Summary: In summary, parathyroid hormone compounds are a major advance in the treatment of osteoporosis. Additional research will enlighten clinicians on the most efficacious way to use them.",
keywords = "Osteoanabolic agent, Osteoporosis, Parathyroid hormone",
author = "Lane, {Nancy E}",
year = "2004",
month = "7",
doi = "10.1097/01.bor.0000129721.98691.cb",
language = "English (US)",
volume = "16",
pages = "457--463",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Parathyroid hormone

T2 - Evolving therapeutic concepts

AU - Lane, Nancy E

PY - 2004/7

Y1 - 2004/7

N2 - Purpose of review: Osteoporosis results from a loss of bone mass and structure such that bones break with very little trauma. To reduce bone loss and improve strength, antiresorptive agents have been instituted. Just more than a year ago, a 34-amino acid fragment of parathyroid hormone (recombinant human parathyroid hormone 1-34) was approved for the treatment of osteoporosis. The parathyroid hormone treatment works by stimulating bone formation on all bone surfaces and is referred to as an osteoanabolic agent. The purpose of this article is to review initial phase 2 and phase 3 studies that establish the effectiveness of this agent to treat osteoporosis. Recent findings: In addition, studies that use parathyroid hormone in combination with antiresorptive agents and sequentially are reviewed. Last, unresolved issues related to the duration of use of parathyroid hormone are discussed. Summary: In summary, parathyroid hormone compounds are a major advance in the treatment of osteoporosis. Additional research will enlighten clinicians on the most efficacious way to use them.

AB - Purpose of review: Osteoporosis results from a loss of bone mass and structure such that bones break with very little trauma. To reduce bone loss and improve strength, antiresorptive agents have been instituted. Just more than a year ago, a 34-amino acid fragment of parathyroid hormone (recombinant human parathyroid hormone 1-34) was approved for the treatment of osteoporosis. The parathyroid hormone treatment works by stimulating bone formation on all bone surfaces and is referred to as an osteoanabolic agent. The purpose of this article is to review initial phase 2 and phase 3 studies that establish the effectiveness of this agent to treat osteoporosis. Recent findings: In addition, studies that use parathyroid hormone in combination with antiresorptive agents and sequentially are reviewed. Last, unresolved issues related to the duration of use of parathyroid hormone are discussed. Summary: In summary, parathyroid hormone compounds are a major advance in the treatment of osteoporosis. Additional research will enlighten clinicians on the most efficacious way to use them.

KW - Osteoanabolic agent

KW - Osteoporosis

KW - Parathyroid hormone

UR - http://www.scopus.com/inward/record.url?scp=3042629351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042629351&partnerID=8YFLogxK

U2 - 10.1097/01.bor.0000129721.98691.cb

DO - 10.1097/01.bor.0000129721.98691.cb

M3 - Article

C2 - 15201611

AN - SCOPUS:3042629351

VL - 16

SP - 457

EP - 463

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 4

ER -